ArticleTropical animal health and production2025
Therapeutic efficacy of moxifloxacin and marbofloxacin against mastitis in buffalo.
Article in Tropical animal health and production, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mastitis is a common economically important disease of dairy buffaloes. Antibiotic resistance is the most cited reason behind the failure of clinical mastitis treatment in buffaloes. Selection of antibiotic after antibiotic sensitivity test is the key to avoid multidrug resistance (MDR) for mastitis therapy. Therefore, the present research work was carried out to evaluate efficacy of moxifloxacin and marbofloxacin in clinical mastitis in buffaloes based on the sensitivity against common mastitic bacteria in buffaloes. Total twenty clinical mastitis positive buffaloes were selected after screening of 129 lactating buffaloes by strip cup test and clinical signs, in and around Parbhani area. The selected buffaloes were divided into 2 groups, 10 animals in each. Group I was treated with injection Moxifloxacin @ 5 mg/kg BW IM for 5 days and group II received injection Marbofloxacin @ 2 mg/kg BW IM for 5 days. Supportive treatment was given in both groups as antihistaminic, multivitamins and NSAIDs. The clinical parameters like rectal temperature, heart rate and respiratory rate showed significant improvement in both the treatment groups. Haematolgical study showed significant improvement in TLC, neutrophil and lymphocyte count while apparent but non-significant improvement observed in Hb, PCV, basophil, eosinophil and monocyte count. The most frequent bacteria observed in mastitic samples were Staphylococcus aureus, followed by E. coli, Klesiella spp. and mixed bacterial infection. Marbofloxacin showed highest sensitivity to mastitis causing bacteria followed by Moxifloxacin, Enrofloxacin and Ciprofloxacin. The comparative efficacies in treatment groups were calculated on the basis of improvement in clinical signs, strip cup test and somatic cell count after treatment. Higher efficacy of Marbofloxacin was found (70%) as compared to Moxifloxacin (50%) for treatment of clinical mastitis. Hence, concluded that marbofloxacin could be appropriative antibiotic agent in the treatment of mastitis in buffalo.
Indexed as
Identifiers
39982570What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.